535 related articles for article (PubMed ID: 16012271)
1. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
Potkin SG; Keck PE; Segal S; Ice K; English P
J Clin Psychopharmacol; 2005 Aug; 25(4):301-10. PubMed ID: 16012271
[TBL] [Abstract][Full Text] [Related]
2. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania.
Keck PE; Versiani M; Warrington L; Loebel AD; Horne RL
J Clin Psychiatry; 2009 Jun; 70(6):844-51. PubMed ID: 19573482
[TBL] [Abstract][Full Text] [Related]
4. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
[TBL] [Abstract][Full Text] [Related]
6. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
[TBL] [Abstract][Full Text] [Related]
7. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
8. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
[TBL] [Abstract][Full Text] [Related]
9. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
Harvey PD; Endicott JM; Loebel AD
Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
Keck PE; Reeves KR; Harrigan EP;
J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
[TBL] [Abstract][Full Text] [Related]
12. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
13. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
14. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Hirschfeld RM; Keck PE; Kramer M; Karcher K; Canuso C; Eerdekens M; Grossman F
Am J Psychiatry; 2004 Jun; 161(6):1057-65. PubMed ID: 15169694
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies.
Stahl S; Lombardo I; Loebel A; Mandel FS
J Affect Disord; 2010 Apr; 122(1-2):39-45. PubMed ID: 19616304
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
